Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$56.14 USD

56.14
97,223,380

-7.21 (-11.38%)

Updated Aug 5, 2025 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 246)

Industry: Medical Info Systems

Zacks News

Zacks Equity Research

Teleflex's (TFX) Urolift Drives Market Share, Macro Woes Stay

The commercialization of Teleflex's (TFX) UroLift in Japan has been a significant step toward making this therapy more broadly available to men suffering from BPH.

Zacks Equity Research

BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase

BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.

Zacks Equity Research

Charles River (CRL) Launches Viral Vector Tech Transfer Program

Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.

Zacks Equity Research

SenesTech (SNES) to Gain Market With Evolve's Launch on Amazon

SenesTech (SNES) looks to leverage the convenience and reach of e-commerce to expand its market share.

Zacks Equity Research

Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.

Zacks Equity Research

Reasons to Hold Charles River (CRL) in Your Portfolio Now

Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.

Moumi Mondal headshot

Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?

Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.

Zacks Equity Research

Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst

Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare

Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.

Zacks Equity Research

Here's Why Investors Should Retain ICON (ICLR) Stock Now

Investors remain optimistic about ICON (ICLR) due to its impressive strategic pacts and stable solvency.

Zacks Equity Research

Stereotaxis (STXS) Gets CE Recertification for Approved Products

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock Now

Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.

Zacks Equity Research

Charles River (CRL) Banks on RMS Growth Amid Competition

Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Zacks Equity Research

Zacks Market Edge Highlights: Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco

Wingstop, Super Micro Computer, Medpace, Him & Hers Health and Vita Coco are part of the Zacks Market Edge blog.

Zacks Equity Research

Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial

Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.

Zacks Equity Research

Reasons to Include Alcon (ALC) in Your Portfolio Right Now

New product launches and strong solvency bode well for Alcon (ALC).

Tracey Ryniec headshot

5 Top Ranked Strong Buy Growth Stocks for 2024

Get double digit earnings growth this year.

Zacks Equity Research

Boston Scientific (BSX) Rides on Emerging Markets, MedSurg

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Zacks Equity Research

Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care

Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.

Zacks Equity Research

Globus Medical (GMED) Hits 52-Week High: What's Driving It?

Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.

Zacks Equity Research

Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes

Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.

Zacks Equity Research

Here's Why You Should Buy Haemonetics (HAE) Stock Now

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Zacks Equity Research

Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade

Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.

Zacks Equity Research

Evolus (EOLS) Releases Favorable Dermal Fillers Study Data

The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.